Introduction {#S0001}
============

Metabolic syndrome is a worldwide problem, which refers to a constellation of coronary heart disease (CHD) risk factors including obesity and abdominal fat distribution, disorders of glucose and lipid metabolism, and hypertension \[[@CIT0001], [@CIT0002]\]. In addition, various other abnormalities of uric acid, inflammation, homeostasis, and fibrinolysis are often considered part of this syndrome \[[@CIT0003]\].

The prevalence of metabolic syndrome is increasing and it is considered one of the main threats to human health worldwide \[[@CIT0004]\]. The epidemic correlates with pronounced changes in the environment, behavior and lifestyle \[[@CIT0005]\].

Several studies have suggested that fructose-induced hyperuricemia may play a pathogenic role in metabolic syndrome. This is consistent with the increased consumption of fructose-containing beverages and the epidemic of diabetes and obesity \[[@CIT0006]\]. In contrast to the metabolic effects of other sugars, fructose induces hyperuricemia through the stimulation of nucleotide catabolism via the conversion of hepatic adenosine triphosphate to adenosine diphosphate by fructokinase and it may retard urinary excretion of uric acid \[[@CIT0007]\].

Uric acid induces gene expression of chemokines and growth factors, such as monocyte chemoattractant protein-1 and platelet-derived growth factor, and stimulates proliferation of vascular smooth muscle cells \[[@CIT0008]\].

Another potential mechanism activated by uric acid is oxidative stress. In the extracellular environment, urate can scavenge hydroxyl radical, singlet oxygen and peroxynitrite, especially when combined with ascorbic acid or thiols \[[@CIT0009]\]. On the other hand, uric acid loses its antioxidant ability in the hydrophobic environment \[[@CIT0010]\]. It was shown that soluble uric acid -- alone or combined with peroxynitrite -- stimulates an increase in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and increases production of reactive oxygen species in mature adipocytes, which result in increased protein nitrosylation and lipid oxidation \[[@CIT0011], [@CIT0012]\].

Uric acid also inhibits nitric oxide bioavailability and, because insulin requires nitric oxide to stimulate glucose uptake, there is a possibility that fructose-induced hyperuricemia and insulin resistance are partially prevented by lowering serum uric acid \[[@CIT0013]\].

Recent studies have demonstrated that in the bioactivation of nitrate, nitrite anion is an intermediate and this more reactive compound is further metabolized to nitric oxide, nitrosothiols and other bioactive nitrogen oxide tissues \[[@CIT0014]\].

Administration of nitrate or nitrite to humans and rodents is clearly associated with nitric oxide-like bioactivity, as demonstrated by increases in cyclic guanosine monophosphate formation \[[@CIT0015]\], vasodilatation \[[@CIT0016]\], reduction in blood pressure \[[@CIT0017]\] and inhibition of platelet function \[[@CIT0018]\].

Therefore, this study was designed to investigate and compare the role of the preventive and therapeutic effects of inorganic nitrate and allopurinol on metabolic syndrome features and renovascular complications to improve the role of NO and uric acid in pathogenesis of metabolic syndrome.

Material and methods {#S0002}
====================

Chemicals and drugs {#S20003}
-------------------

Allopurinol was purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA). Normal saline solution (sodium chloride 0.9%) and fructose were purchased from AlGomhoria Pharmaceutical Co. (Cairo, Egypt). Sodium nitrate was obtained from MUP Pharmaceutical Co. (Ismailia, Egypt). All the commercial assay kits were purchased from Bio-diagnostic^®^ (Cairo, Egypt).

Animals {#S20004}
-------

Sixty-four Sprague-Dawley adult male rats (180-200 g) were purchased from the National Research Center, Cairo, Egypt. Animals were housed in wire-mesh cages with a normal light-dark cycle at a constant temperature of 22-24°C throughout the experiment. They were placed on a standard chow ad libitum for 1 week to adapt to the laboratory environment before experiments. The study was designed to avoid suffering and limit the number of animals used and all experimental protocols were approved by the institutional animal care and use committee at the Faculty of Medicine, Suez Canal University (Ismailia, Egypt).

Study design {#S20005}
------------

Two experiments were conducted in this study; rats were divided into four groups in each experiment.

### Experiment I: treatment of fructose-induced hyperuricemia with inorganic nitrate or allopurinol (therapeutic regimen)

To assess the therapeutic effect of either inorganic nitrate or allopurinol in fructose-induced metabolic syndrome, two groups of rats were used. Rats (*n* = 24) were fed a high-fructose diet or a control diet (*n* = 8). The high-fructose diet contained 60% fructose, whereas the control diet contained 46% starch as the carbohydrate. The caloric content of these diets was 3.6 kcal/g and 3.1 kcal/g, respectively \[[@CIT0019]\]. At 4 weeks, blood pressure was measured, blood samples were obtained at 11 a.m. after overnight fasting, and then the fructose-fed group was subdivided into 3 sub-groups of 8 animals each. The untreated fructose group served as a positive control group. The sodium nitrate and allopurinol groups received either sodium nitrate (150 mg/kg) \[[@CIT0020]\] or allopurinol (10 mg/kg) \[[@CIT0020]\] dissolved in normal saline by oral gavage once daily for an additional 6 weeks.

### Experiment II: prevention of fructose-induced hyperuricemia with sodium nitrate or allopurinol (preventive regimen)

To assess their effect in preventing metabolic syndrome, sodium nitrate and allopurinol in the same mentioned doses were initiated on the day when the high-fructose diet was given from week 0 to week 10. Four groups were used in this preventive study: control, fructose, fructose sodium nitrate and fructose_allopurinol (*n* = 8 each).

Measurement of body weight {#S20008}
--------------------------

Rats were pair-fed to ensure equivalent caloric intake, thereby avoiding the influence of different food intake on the metabolic abnormalities. Body weight was measured weekly \[[@CIT0021]\].

Measurement of mean blood pressure {#S20009}
----------------------------------

All animals were preconditioned for mean blood pressure measurements one week before the experiment by the tail-cuff method (Data acquisition system mp140, USA). Blood pressure was measured at baseline, at 4 weeks and at 10 weeks. The mean of three successive measurements was taken \[[@CIT0022]\].

Blood glucose determination and sample collection {#S20010}
-------------------------------------------------

At the end of the 4^th^ week and at the end of the study, rats were fasted overnight and fasting blood glucose was determined with an automatic blood glucose meter (Super Glucocard, Japan) using blood samples from the tail vein. At the end of the study, rats were anesthetized with thiopental sodium (50 mg/kg) \[[@CIT0023]\] and killed by decapitation. Blood samples were collected by cardiac puncture, centrifuged at 2000 rpm for 15 min within 30 min of collection and stored at --80°C until assayed.

Enzyme-linked immunosorbent assay for insulin {#S20011}
---------------------------------------------

Serum insulin was determined at the 4^th^ week and the end of the study using a rat insulin ultrasensitive ELISA kit (Crystal Chem Inc., Downers Grove, IL 60515, USA) according to the manufacturer\'s instructions. Reactions were quantified by optical density using an automated ELISA reader.

Calculation of insulin resistance {#S20012}
---------------------------------

Insulin resistance was determined using the homeostasis model assessment index for insulin resistance (HOMA-IR) using the following formula: HOMA-IR index = \[fasting glucose (mmol/l) × fasting insulin (µU/ml)\]/22.5 \[[@CIT0024]\]. To assess insulin sensitivity, the quantitative insulin sensitivity check index was used: (QUICKI) = 1/(log fasting insulin (µU/ml) + log fasting glucose (mg/dl)). QUICKI predicts insulin sensitivity, with lower values representing more insulin resistance \[[@CIT0025]\].

Processing of adipose tissue {#S20013}
----------------------------

The retroperitoneal adipose tissue from each rat was totally removed and weighed at the end of the study to be used for calculation of the adiposity index: adipose tissue index = (retroperitoneal adipose tissue weight / body weight) × 100.

Biochemical assays {#S20014}
------------------

### Serum uric acid, creatinine and urea

Serum uric acid was determined at 4 weeks and at the end of the study \[[@CIT0026]\]. Serum creatinine \[[@CIT0026]\] and urea \[[@CIT0027]\] levels were measured at the end of the study.

### Urinary uric acid

At the end of the study, rats in each group were individually housed in metabolic cages for 24 h urine collection, and continued to have free access to water and food. Urine samples were used for estimation of uric acid \[[@CIT0026]\].

### Lipid profile

Serum triglycerides (TGs) \[[@CIT0028]\], total cholesterol \[[@CIT0029]\] and high density lipoprotein cholesterol (HDL-C) \[[@CIT0030]\] were measured at the end of the study. Low density lipoprotein (LDL) was calculated according to the following formula: serum LDL level = total cholesterol -- ((triglycerides/5) + HDL) \[[@CIT0031]\].

### Assay of total nitrite in renal tissue homogenate (Griess reaction)

The total nitrite concentration level was measured in 100 mg renal tissue homogenate -- as an indicator for nitric oxide production -- at the end of the study according to the method described by Green *et al*. \[[@CIT0032]\]. All the colorimetric assays were performed using a UV-visible spectrophotometer (UV-1601-PC, Shimadzu, Japan).

Statistical analysis {#S20019}
--------------------

The data were coded and entered using the statistical package SPSS version 17 (Chicago, IL, USA). The results were expressed as mean ± S.E.M. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by post hoc multiple comparison Bonferroni test, to test the significance of differences among group means. P value of \< 0.05 was considered statistically significant at confidence interval 95%.

Results {#S0020}
=======

Effect of the high-fructose diet in induction of features of metabolic syndrome {#S20021}
-------------------------------------------------------------------------------

Oral administration of a high-fructose diet for 4 weeks in rats resulted in development of features of metabolic syndrome manifested by significant increase (*p* \< 0.05) in mean blood pressure (BP), serum uric acid and fasting insulin levels with mean values of 125.2 ±7.8 mm Hg, 5.9 ±0.5 mg/dl and 53 ±1.7 µU/l respectively as compared with rats fed a control diet with mean values of 62.7 ±4.7 mm Hg, 1.8 ±0.2 mg/dl and 42.2 ±1.8 µU/l respectively. On the other hand, the body weight of fructose-fed rats did not differ significantly compared with rats fed a normal diet: 225 ±10.2 g vs. 231 ±10.1 g respectively (data not shown).

Mean blood pressure {#S20022}
-------------------

To examine the effect of sodium nitrate and allopurinol after development of metabolic syndrome, one-third of the fructose-fed rats were treated with sodium nitrate and one-third were treated with allopurinol for 6 additional weeks. Sodium nitrate significantly (*p* \< 0.05) reduced mean blood pressure while allopurinol induced a non-significant decrease in blood pressure compared to fructose-fed rats ([Figure 1A](#F0001){ref-type="fig"}). The present study also examined the effectiveness of sodium nitrate and allopurinol in preventing the development of metabolic syndrome. The drugs were given simultaneously with the high-fructose diet from the starting point to avoid fructose-induced metabolic syndrome. As shown in [Figure 1B](#F0001){ref-type="fig"}, the elevation of mean blood pressure induced by the high-fructose diet was significantly (*p* \< 0.05) decreased over the 10-week period by using any of the drugs.

![Mean blood pressure (BP) of experimental groups after 6 weeks (**A**) or 10 weeks (**B**) oral therapy of sodium nitrate (sod. Nit) 150 mg/kg/day or allopurinol (Allo) 10 mg/kg/day in rats with metabolic syndrome induced by 60% fructose in diet. Results are mean ± SEM and analyzed by one-way ANOVA and Bonferroni post-hoc test\
\*Significant compared to control group, \#significant compared to fructose group](AMS-10-20252-g001){#F0001}

Fasting blood glucose, insulin and insulin resistance {#S20023}
-----------------------------------------------------

Although fructose-fed rats did not develop significant fasting hyperglycemia, they developed significant (*p* \< 0.05) fasting hyperinsulinemia and a significant (*p* \< 0.05) increase in insulin resistance compared to controls. Insulin resistance, as measured by HOMA-IR and QUICKI, was reversed significantly by either sodium nitrate or allopurinol compared to the fructose group in the therapeutic or preventive regimen. In addition, both drugs also induced a significant decrease in insulin level in the preventive regimen ([Table I](#T0001){ref-type="table"}).

###### 

Fasting blood glucose, insulin, HOMA-IR and QUICKI in fructose-induced metabolic syndrome in rats after therapeutic and preventive interventions with either sodium nitrate or allopurinol

  Parameter                    Therapeutic regimen   Preventive regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  ---------------------------- --------------------- ---------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ -------- ------------ ---------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -------
  Fasting glucose \[mmol/l\]   5.9 ±0.4              7.5 ±1.2                                       6.2 ±0.9                                                                          6.0 ±1.3                                                                                                           5.54     5.9 ±0.4     7.2 ±0.4                                       6.2 ±0.3                                                                         6.3 ±0.4                                                                         6.54
  Fasting insulin \[µU/ml\]    49.4 ±3.5             61.8 ±1.4[\*](#TF0001){ref-type="table-fn"}    59.3 ±3.1[\*](#TF0001){ref-type="table-fn"}                                       61.2 ±3.1[\*](#TF0001){ref-type="table-fn"}                                                                        14.56    49.4 ±3.5    61.8 ±4.4[\*](#TF0001){ref-type="table-fn"}    55.8 ±2.1[\*](#TF0001){ref-type="table-fn"} [\#](#TF0002){ref-type="table-fn"}   52.9 ±2.7[\#](#TF0002){ref-type="table-fn"}                                      18.35
  HOMA-IR                      13 ±0.9               20.6 ±2.2[\*](#TF0001){ref-type="table-fn"}    16.3 ±1.9[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}    16.3 ±1.4[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}                                     16.32    13 ±0.9      19.8 ±0.9[\*](#TF0001){ref-type="table-fn"}    15.3 ±0.4[\#](#TF0002){ref-type="table-fn"}                                      14.8 ±0.8[\#](#TF0002){ref-type="table-fn"}                                      16.52
  QUICKI                       0.27 ±0.02            0.23 ±0.01[\*](#TF0001){ref-type="table-fn"}   0.25 ±0.01[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}   0.25 ±0.00[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}                                    17.11    0.27 ±0.02   0.24 ±0.09[\*](#TF0001){ref-type="table-fn"}   0.26 ±0.01[\#](#TF0002){ref-type="table-fn"}                                     0.26 ±0.02[\#](#TF0002){ref-type="table-fn"}                                     16.39
  Body weight \[g\]            287.5 ±8              255.0 ±12.4                                    270.3 ±8                                                                          284.5 ±7.4                                                                                                         2.64     287.5 ±8     280.0 ±3.8                                     285.3 ±4.5                                                                       270.0 ±3.9                                                                       1.07
  Adipose tissue \[g\]         16.0 ±1.2             32.9 ±1.5[\*](#TF0001){ref-type="table-fn"}    29.5 ±0.8[\*](#TF0001){ref-type="table-fn"}                                       21.1 ±1.9[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"},[@](#TF0003){ref-type="table-fn"}   30.837   16.0 ±1.2    32.7 ±1.5[\*](#TF0001){ref-type="table-fn"}    24.1 ±0.8[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}   21.1 ±1.9[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}   34.0
  Adiposity index              5.6 ±0.4              12.9 ±1.1[\*](#TF0001){ref-type="table-fn"}    10.9 ±0.3[\*](#TF0001){ref-type="table-fn"}                                       7.4 ±0.6[\#](#TF0002){ref-type="table-fn"},[@](#TF0003){ref-type="table-fn"}                                       27.06    5.6 ±0.4     11.7 ±0.9[\*](#TF0001){ref-type="table-fn"}    8.4 ±0.6[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}    7.8 ±0.1[\*](#TF0001){ref-type="table-fn"},[\#](#TF0002){ref-type="table-fn"}    27.82

HOMA-IR -- homeostatic model assessment for insulin resistance. QUICKI -- quantitative insulin sensitivity check index. Rats fed 60% fructose diet or a control diet for 10 weeks. Oral sodium nitrate 150 mg/kg/d or allopurinol (Allo) 10 mg/kg/day was used for 6 weeks in the therapeutic regimen or for 10 weeks in the preventive regimen. Results are mean ± SEM and analyzed by one-way ANOVA and Bonferroni post-hoc test. N = 8.

Significant compared to control group at *p* \< 0.05

Significant compared to fructose group at *p* \< 0.05

Significant compared to sodium nitrate group at *p* \< 0.05

Adiposity index {#S20024}
---------------

Although body weight did not change significantly between fructose-fed rats and controls, the adipose tissue index was significantly (*p* \< 0.05) increased in fructose-fed rats compared to controls. In the therapeutic regimen, allopurinol significantly (*p* \< 0.05) prevented the increase in adiposity index compared to fructose-fed rats and sodium nitrate-treated rats. On the other hand, both drugs resulted in a decrease in the adiposity index in the preventive regimen ([Table I](#T0001){ref-type="table"}).

Serum and urinary uric acid and serum creatinine and urea {#S20025}
---------------------------------------------------------

In accordance with the mechanism of action of allopurinol, in the therapeutic regimen, it showed a significant (*p* \< 0.05) decrease in uric acid serum level, whereas the fructose-fed rats that did not receive treatment or received sodium nitrate continued to be hyperuricemic ([Figure 2A](#F0002){ref-type="fig"}).

![Serum uric acid (mg/dl), urinary uric acid (mg/day) and serum creatinine and urea (mg/dl) of experimental groups. Serum uric acid (**A, B**), urinary uric acid (mg/day) (**C, D**) and serum creatinine and urea (**E, F**) after 6 weeks (**A, C, E**) or 10 weeks (**B, D, F**) oral therapy of sodium nitrate (sod. Nit) 150 mg/kg/day or allopurinol (Allo) 10 mg/kg/day in rats with metabolic syndrome induced by 60% fructose in diet\
Results are mean ± SEM and analyzed by one-way ANOVA and Bonferroni post-hoc test. ^\*^Significant compared to control group, ^\#^significant compared to fructose group, ^@^significant compared to sodium nitrate group](AMS-10-20252-g002){#F0002}

On the other hand, in the preventive regimen, both sodium nitrate and allopurinol resulted in a significant decrease in uric acid serum level compared to fructose-fed non-treated rats and the beneficial effect of allopurinol was significant compared to sodium nitrate (*p* \< 0.05, [Figure 2B](#F0002){ref-type="fig"}). In addition, we examined the urinary excretion of uric acid in these animals to clarify the mechanisms of hyperuricemia in fructose-fed rats. Fructose-fed rats had lower urinary excretion of uric acid. Interestingly, allopurinol -- but not sodium nitrate -- significantly prevented and reversed the reduced excretion of uric acid in fructose-fed rats (*p* \< 0.05, [Figures 2C](#F0002){ref-type="fig"}, [2D](#F0002){ref-type="fig"}). The urinary excretion of uric acid was normalized in the preventive regimen.

Again, the high-fructose diet induced a significant (*p* \< 0.05) increase in serum creatinine and urea compared to controls. Administration of either sodium nitrate or allopurinol in both regimens resulted in improvement of renal function as manifested by a significant decrease in these serum levels compared to fructose-fed rats (*p* \< 0.05, [Figures 2E](#F0002){ref-type="fig"}, [2F](#F0002){ref-type="fig"}).

Lipid profile {#S20026}
-------------

Regarding lipid profile, the results of the current study showed that fructose-fed rats developed a significant (*p* \< 0.05) increase in serum TGs, cholesterol and LDL and a significant (*p* \< 0.05) decrease in HDL serum levels compared to controls. Administration of sodium nitrate resulted in a significant decrease in TGs in both therapeutic and preventive regimens and both sodium nitrate and allopurinol significantly normalized HDL serum level in both regimens compared to fructose-fed rats (*p* \< 0.05, [Figures 3A](#F0003){ref-type="fig"}, [3B](#F0003){ref-type="fig"}). On the other hand, the tested drugs resulted in a non-significant improvement in total cholesterol and LDL serum levels compared to fructose alone-fed rats (*p* \> 0.05, data not shown).

![Serum triglycerides (TGs) and serum high-density lipoproteins (HDL) after 6 weeks (**A**) or 10 weeks (**B**) oral therapy of sodium nitrate (sod. Nit) 150 mg/kg/day or allopurinol (Allo) 10 mg/kg/day in metabolic syndrome induced by 60% fructose in diet\
Results are mean ± SEM and analyzed by one-way ANOVA and Bonferroni post-hoc test. ^\*^Significant compared to control group, ^\#^significant compared to fructose group](AMS-10-20252-g003){#F0003}

Nitrite level in renal tissue homogenate {#S20027}
----------------------------------------

A shown in [Figure 4](#F0004){ref-type="fig"}, nitric oxide level was measured in renal tissue homogenate. Induction of metabolic syndrome by 60% fructose in diet induced a significant (*p* \< 0.05) decrease in this level. In the therapeutic regimen, administration of sodium nitrate significantly (*p* \< 0.05) increased its level again compared to the fructose-fed group and compared to the allopurinol-treated group ([Figure 4A](#F0004){ref-type="fig"}), while in the preventive regimen, both drugs induced a significant increase in its level compared to the fructose-fed group (*p* \< 0.05, [Figure 4B](#F0004){ref-type="fig"}).

![Nitrite level (NO) in 100 mg renal tissue homogenate of experimental groups after 6 weeks (**A**) or 10 weeks (**B**) oral therapy of sodium nitrate (sod. Nit) 150 mg/kg/day or allopurinol (Allo) 10 mg/kg/day in rats with metabolic syndrome induced by 60% fructose in diet\
Results are mean ± SEM and analyzed by one-way ANOVA and Bonferroni post-hoc test. ^\*^Significant compared to control group, ^\#^significant compared to fructose group, ^\$^significant compared to allopurinol group](AMS-10-20252-g004){#F0004}

Discussion {#S0028}
==========

We have succeeded in inducing metabolic syndrome in experimental rats by administering 60% fructose for 4 weeks in the diet. Features of the syndrome were in the form of hypertension, hyperuricemia and hyperinsulinemia in accordance with Roncal *et al*. \[[@CIT0022]\].

In an attempt to compare the effect of sodium nitrate and allopurinol on attenuating these mentioned features, sodium nitrate showed a significantly higher effect in reducing the mean arterial blood pressure compared to allopurinol. This could be attributed to the effect of sodium nitrate in inducing nitric oxide-like bioactivity in humans including a robust reduction in blood pressure, inhibition of platelet aggregation and improvement of endothelial function \[[@CIT0015], [@CIT0020], [@CIT0033]\]. On the other hand, and in accordance with our study, it was found that allopurinol had a partial effect in preventing the rise in arterial blood pressure when compared to captopril, a potent antihypertensive drug \[[@CIT0022]\].

However, allopurinol was a potent drug in reducing both the hyperuricemia and the increase in the adipose tissue index induced by the metabolic syndrome compared to the effect of sodium nitrate. There is supporting evidence that uric acid may have a pathogenic role in metabolic syndrome. Hyperuricemia has been found to predict the development of both obesity and type II diabetes \[[@CIT0034]\], as well as in secondary insulin resistance syndromes such as that associated with gout \[[@CIT0035]\] or diuretic usage \[[@CIT0036]\]. These data introduce the novel concept that uric acid may have a causal role in metabolic syndrome.

It is known that although fructose likely increases the production of uric acid, decreased urinary uric acid excretion could be due to an increase in uric acid reabsorption in proximal tubules \[[@CIT0025]\]. The beneficial hypouricemic effect of allopurinol may be explained either by decreased uric acid synthesis \[[@CIT0005]\] or according to Johnson *et al*. \[[@CIT0037]\], who stated that hyperuricemic rats are known to develop renal vasoconstriction with a reduction of renal blood flow, and this is reversed by allopurinol. In turn, an increase in renal blood flow will result in increased uric acid excretion. According to that, by improving endothelial dysfunction and renal blood flow, the lowering of uric acid could paradoxically enhance excretion.

Regarding insulin resistance, our results were in accordance with previous studies which suggested that insulin resistance or hyperinsulinemia is associated with metabolic syndrome \[[@CIT0038]\], enhanced urate reabsorption and reduced urate excretion in the kidney, leading to elevated serum uric acid concentrations \[[@CIT0039]\]. Consistent with this observation is the finding that drugs which improve insulin sensitivity and lower insulin levels also reduce the level of serum uric acid in diabetic patients \[[@CIT0040]\].

Uric acid potently reduces endothelial NO bioavailability in both cell culture and in experimental animal models \[[@CIT0041]\]. In turn, reducing endothelial NO levels is a known mechanism for inducing insulin resistance \[[@CIT0042]\]; thus endothelial NOS-deficient mice exhibit the features of metabolic syndrome \[[@CIT0020]\]. This can be explained as insulin stimulates glucose uptake in skeletal muscle by increasing blood flow to these tissues through a nitric oxide-dependent pathway \[[@CIT0042]\]. According to this, our study showed that allopurinol or sodium nitrate may have a beneficial role in metabolic syndrome by blocking hyperuricemia-induced endothelial dysfunction or providing nitric oxide to tissues respectively, a finding which was previously supported by many studies \[[@CIT0005], [@CIT0019]\].

Recent epidemiological evidence indicated that hyperuricemia might be a risk factor for renal dysfunction \[[@CIT0043], [@CIT0044]\]. In accordance with the previous studies, the current study showed that fructose resulted in hyperuricemia and attenuated renal function manifested by increase in serum creatinine and urea. On the other hand, allopurinol and sodium nitrate resulted in improvement of kidney function, probably due to hypouricemic properties and increased nitric oxide production respectively.

A recent study demonstrated that fructose up-regulated the expression levels of renal specific transporters (rRST) and down-regulated the expression levels of organic anion transporters (rOAT) and organic cation transporters (rOCT1 and rOCT2), with elevation of the regulator prostaglandin E~2~ (PGE~2~) and nitric oxide reduction, which might lead to excessive accumulation of endogenous and exogenous toxins, resulting in renal damage in fructose-fed rats. The dysregulation of these transporters, in addition to PGE~2~ elevation and nitric oxide reduction, was reversed by allopurinol, rutin and quercetin \[[@CIT0021]\].

Reviewing the effect on the lipid profile, we noticed that both drugs significantly increased HDL serum level but no significant effect was reported in the case of cholesterol or low-density lipoprotein serum levels. For the triglycerides, only sodium nitrate showed a significant decrease in its level in both therapeutic and prophylactic intervention. This is very consistent with the results of Carlström *et al*. \[[@CIT0020]\], who reported that nitrate-treated endothelial nitric oxide synthase-deficient mice displayed lower levels of circulating triglycerides compared to untreated animals.

Although the role of uric acid in the metabolism of triglycerides remains unknown, uric acid might be involved in either the overproduction or the reduction of clearance of triglycerides. A decrease in the clearance of triglycerides in fructose-fed rats has been attributed to a reduction in lipoprotein lipase activity in endothelial cells \[[@CIT0044]\]. An alternative explanation is the possibility that the de novo increase in purine synthesis observed in fructose-fed rats may be pathogenetically linked to hepatic fatty acid synthesis, resulting in overproduction of triglycerides \[[@CIT0046]\].

In previous studies, it was reported that lowering uric acid improves dyslipidemia, which is consistent with our work \[[@CIT0005], [@CIT0047]\].

Regarding the potent effect of nitrates in increasing the tissue nitric oxide compared to allopurinol, we can explain that by the recently discovered ability of inorganic nitrates to be reduced to nitrite and then nitric oxide and other bioactive nitrogen oxides. In that way the deficiency in nitric oxide accompanying the metabolic syndrome could be replenished. It was assumed by certain studies that this deficiency is the result of polymorphism in the endothelial nitric oxide synthase gene in humans \[[@CIT0020], [@CIT0048], [@CIT0049]\].

Allopurinol also blocks oxidants generated by the xanthine oxidase pathway. Oxidants are involved in the pathogenesis of diabetes and its complications. It is therefore possible that the beneficial effects of allopurinol in metabolic syndrome may be attributed, in part, to the lowering of oxidants in addition to its effect on uric acid \[[@CIT0010]\].

To test their prophylactic effects, we introduced both drugs from the beginning of the experiment with the same high-fructose diet in two other groups. All the features of metabolic syndrome were prevented: elevation of uric acid and mean arterial blood pressure, insulin resistance, hypertriglyceridemia and decreased HDL, disturbance in adipose tissue index, elevated serum creatinine and urea, decrease in renal nitric oxide. These results turn our attention to the importance of enriching the daily diet with extensive intake of vegetables, the dominant dietary source of nitrate compounds \[[@CIT0020], [@CIT0050]\].

In conclusion, from the foregoing we can conclude that in metabolic syndrome we cannot count on allopurinol alone in dealing with the elevated blood pressure, but sodium nitrate should be considered first. At the same time, when considering hyperuricemia and dyslipidemia as fundamental disturbances in that syndrome, we proved that allopurinol is the treatment of choice. Our study proved the efficacy of each tested drug to partially attenuate the components of the metabolic syndrome, but in different ways.

Our fundamental recommendation is to test the efficacy of combining both of them. We hypothesize that adding their effects together could have great promise in reversing most of the features of metabolic syndrome.
